Selank: a Russian research compound with anxiolytic history
A peptide with a real clinical record — just not one built within the FDA regulatory framework.
TL;DR
- Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.
- Russian clinical studies have investigated selank for generalized anxiety; it is registered as a pharmaceutical in Russia but has not undergone FDA evaluation.
- FDA removed selank from Category 2 on September 27, 2024. As of September 14, 2026, selank is not in any FDA 503A category and is not on the 503A bulks list.
What it is
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a seven-amino-acid peptide created by appending a tripeptide stabilizing sequence (Pro-Gly-Pro) to the four-amino-acid sequence of tuftsin, an endogenous peptide produced by the spleen. Tuftsin has immunomodulatory properties; selank was designed to extend its stability and add anxiolytic effects. It is administered intranasally — the peptide is too hydrophilic for significant oral bioavailability and too large for straightforward subcutaneous delivery at the doses used in research. In Russia, it has been approved as a pharmaceutical since 2009 under the name "Selank" for anxiety-related indications.
How it works
Selank's mechanism is not fully characterized. Proposed effects include modulation of the GABAergic system (the pathway through which most benzodiazepines act), influence on serotonin transporter expression, and effects on brain-derived neurotrophic factor (BDNF) — a protein involved in neuronal health and plasticity. Animal studies have shown anxiolytic effects in rodent models without the sedation or dependence concerns associated with classical benzodiazepines. Whether these mechanisms translate cleanly to humans at clinically meaningful doses via intranasal administration has not been established through FDA-independent trials.
Who asks about it
Selank comes up in conversations about cognitive performance and anxiety management, often from people who are frustrated with conventional anxiolytics and looking for alternatives with different side-effect profiles. It also appears in discussions about peptide-based nootropics. The appeal is understandable — anxiety and cognitive performance are genuine quality-of-life concerns for many people in midlife.
What the research says
A clinical trial published in Bulletin of Experimental Biology and Medicine (Semenova et al., 2010) evaluated selank in patients with generalized anxiety disorder and neurasthenia. Participants receiving selank showed improvement on anxiety rating scales compared to baseline, and the authors reported a favorable tolerability profile. However, this trial was conducted in Russia with a study population and methodology that has not been independently replicated in Western clinical settings. A search of ClinicalTrials.gov finds no completed or active US trials for selank as of this writing. The Russian literature is real; independent external validation remains absent.
What to know before considering it
FDA removed selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. Even if its regulatory status changes, intranasal peptide delivery introduces its own pharmacokinetic variables that require careful clinical evaluation.
The Halftime POV
Selank represents a category of compounds that have genuine clinical histories in one regulatory context and essentially no formal history in another. That gap — between Russian pharmaceutical approval and FDA evaluation — is significant, and it's not one that anecdote can bridge. The underlying question it raises, around non-sedating anxiolysis, is worth taking seriously. The path to answering it reliably runs through independent clinical trials.
Related reading:
FAQ
Q: What is Selank? A: Selank is a synthetic heptapeptide analog of tuftsin — a naturally occurring immunomodulatory tetrapeptide. It was developed in Russia and has been used clinically there for anxiety and cognitive enhancement. It is not FDA-evaluated. FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list.
Q: What does the published research show about Selank? A: Published Russian clinical literature describes anxiolytic effects in patients with generalized anxiety disorder, with some studies comparing it favorably to benzodiazepines for certain endpoints. These studies were conducted in Russia and are not replicated in US FDA-standard randomized controlled trials. The evidence base is real but geographically concentrated and not FDA-reviewed.
Q: Is Selank available in the United States? A: FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Any source claiming to provide Selank through a 503A pharmacy in the US is making a claim that warrants verification.
Disclaimer
FDA removed selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, selank is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Semenova TP et al. "Selank and its component peptides affect anxiety and serotonin metabolism in the brain." — Bull Exp Biol Med, 2010
- Uchakina ON et al. "Immunomodulatory effects of selank in patients with anxiety-asthenic disorders." — Zh Nevrol Psikhiatr Im S S Korsakova, 2008
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Selank?
Selank is a synthetic heptapeptide analog of tuftsin — a naturally occurring immunomodulatory tetrapeptide. It was developed in Russia and has been used clinically there for anxiety and cognitive enhancement. It is not FDA-evaluated. FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list.
What does the published research show about Selank?
Published Russian clinical literature describes anxiolytic effects in patients with generalized anxiety disorder, with some studies comparing it favorably to benzodiazepines for certain endpoints. These studies were conducted in Russia and are not replicated in US FDA-standard randomized controlled trials. The evidence base is real but geographically concentrated and not FDA-reviewed.
Is Selank available in the United States?
FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Any source claiming to provide Selank through a 503A pharmacy in the US is making a claim that warrants verification.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.